Found: 23
Select item for more details and to access through your institution.
"Omics" and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Selection of monoclonal antibodies which induce internalization and phosphorylation of P185.
- Published in:
- International Journal of Cancer, 1991, v. 47, n. 6, p. 933, doi. 10.1002/ijc.2910470625
- By:
- Publication type:
- Article
Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
- Published in:
- Journal of Cellular Biochemistry, 1999, v. 73, n. 4, p. 522, doi. 10.1002/(SICI)1097-4644(19990615)73:4<522::AID-JCB10>3.0.CO;2-4
- By:
- Publication type:
- Article
Colocalization of the p185.
- Published in:
- Journal of Cellular Biochemistry, 1994, v. 55, n. 4, p. 409, doi. 10.1002/jcb.240550402
- By:
- Publication type:
- Article
Biologic and therapeutic role of HER2 in cancer.
- Published in:
- Oncogene, 2003, v. 22, n. 42, p. 6570, doi. 10.1038/sj.onc.1206779
- By:
- Publication type:
- Article
Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens.
- Published in:
- Cancers, 2014, v. 6, n. 3, p. 1753, doi. 10.3390/cancers6031753
- By:
- Publication type:
- Article
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 128, n. 1, p. 147, doi. 10.1007/s10549-011-1484-4
- By:
- Publication type:
- Article
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
- Published in:
- Breast Cancer Research & Treatment, 2008, v. 112, n. 1, p. 25
- By:
- Publication type:
- Article
Role of proliferation in HER2 status predicted response to doxorubicin.
- Published in:
- International Journal of Cancer, 2003, v. 105, n. 4, p. 568, doi. 10.1002/ijc.11113
- By:
- Publication type:
- Article
PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model.
- Published in:
- Journal of Nuclear Medicine, 2012, v. 53, n. 10, p. 1654, doi. 10.2967/jnumed.112.108068
- By:
- Publication type:
- Article
Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.
- Published in:
- Journal of Cellular Physiology, 2015, v. 230, n. 11, p. 2661, doi. 10.1002/jcp.24968
- By:
- Publication type:
- Article
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.
- Published in:
- Journal of Cellular Physiology, 2012, v. 227, n. 2, p. 658, doi. 10.1002/jcp.22773
- By:
- Publication type:
- Article
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
- Published in:
- Journal of Cellular Physiology, 2010, v. 225, n. 1, p. 256, doi. 10.1002/jcp.22257
- By:
- Publication type:
- Article
Diadenosines as FHIT‐ness instructors.
- Published in:
- Journal of Cellular Physiology, 2006, v. 208, n. 2, p. 274, doi. 10.1002/jcp.20633
- By:
- Publication type:
- Article
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
- Published in:
- Journal of Cellular Physiology, 2006, v. 207, n. 2, p. 420, doi. 10.1002/jcp.20588
- By:
- Publication type:
- Article
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level(Iressa is a trademark of the AstraZeneca group of companies.)
- Published in:
- Journal of Cellular Physiology, 2004, v. 198, n. 2, p. 259, doi. 10.1002/jcp.10411
- By:
- Publication type:
- Article
Role of HER2 gene overexpression in breast carcinoma.
- Published in:
- Journal of Cellular Physiology, 2000, v. 182, n. 2, p. 150, doi. 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E
- By:
- Publication type:
- Article
Distinct characteristics of heregulin signals mediated by HER3 or HER4.
- Published in:
- Journal of Cellular Physiology, 1997, v. 173, n. 2, p. 187, doi. 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D
- By:
- Publication type:
- Article
Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 2, p. 434, doi. 10.3390/cells9020434
- By:
- Publication type:
- Article
Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 2, p. 181, doi. 10.3390/cells8020181
- By:
- Publication type:
- Article
HER2 splice variants and their relevance in breast cancer.
- Published in:
- Journal of Nucleic Acids Investigation, 2011, v. 2, n. 1-3, p. 52, doi. 10.4081/jnai.2011.2454
- By:
- Publication type:
- Article
PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.
- Published in:
- Molecular Oncology, 2014, v. 8, n. 5, p. 968, doi. 10.1016/j.molonc.2014.03.015
- By:
- Publication type:
- Article